Could a common diabetes drug slash heart risks in hypertension?

NCT ID NCT06804161

Recruiting now Disease control Sponsor: Prof. Dr. med. Ingo Eitel Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a daily SGLT2 inhibitor pill can reduce heart attacks, strokes, and other cardiovascular events in 3,000 adults aged 60+ with high blood pressure and a history of heart or blood vessel problems. Participants will receive either the drug or a placebo for several years. The goal is to see if this drug, already used for diabetes and heart failure, can offer extra protection for people with hypertension.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SGLT2 inhibitor (a type of diabetes drug that also lowers blood pressure)
What this could lead to: If successful, this could lead to a new standard treatment to prevent heart attacks and strokes in people with high blood pressure.
What could go wrong: This is a large phase 3 trial, but SGLT2 inhibitors are already used for diabetes and heart failure, so the added benefit for hypertension alone may be modest. Side effects like dehydration or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL HYPERTENSION

Contacts and locations

Locations

Universität zu Lübeck
RECRUITING

Lübeck, Schleswig-Holstein, 23538, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.